Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | SHBG | P04278 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22416728 | 0.90 | KDM4E (0.48) | KDM4EKCNH2ALDH1A1HSD17B10DPP7 | |
| SCHEMBL1485686 | 0.90 | KDM4E (0.48) | KDM4EKCNH2ALDH1A1HSD17B10DPP7 | |
| SCHEMBL24728 | 0.90 | — | — | |
| SCHEMBL22316957 | 0.90 | KDM4E (0.48) | KDM4EKCNH2ALDH1A1HSD17B10DPP7 | |
| SCHEMBL22790769 | 0.90 | KDM4E (0.48) | KDM4EKCNH2ALDH1A1HSD17B10DPP7 | |
| SCHEMBL1037554 | 0.90 | KDM4E (0.48) | KDM4EKCNH2ALDH1A1HSD17B10DPP7 | |
| SCHEMBL11573949 | 0.90 | KDM4E (0.48) | KDM4EKCNH2ALDH1A1HSD17B10DPP7 | |
| SCHEMBL23119845 | 0.87 | KCNH2 (0.44) | KCNH2 | |
| SCHEMBL14371896 | 0.87 | KCNH2 (0.44) | KCNH2 | |
| Fluoride SCHEMBL9620604 | 0.87 | KDM4E (0.46) | KDM4EKCNH2ALDH1A1HSD17B10DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426607-B2 | Substituted amino-benzimidazoles, medicaments comprimising said compound, their use and their method of manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-23 | — | — | US | disclosed |
| US-20110288139-A1 | SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRIMISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | US | disclosed |
| EP-2245016-A1 | SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE | Boehringer Ingelheim International GmbH (DE) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009092566-A1 | SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-30 | — | — | WO | disclosed |
| US-3947463-A | Certain 2-amino-nicotinonitrile derivatives | CASSELLA FARBWERKE MAINKUR AG (DT) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288139-A1 | SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRIMISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE | PSEN1, AADAT, PSEN2 | KDM4E 532/4885KCNH2 3970/4885ALDH1A1 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.